Patient information
| Patient # | Study arm | Soft tissue mets. at baseline | Bone mets. at baseline | IRAE greater than Gr 1a (week of occurrence) | Progression-free survival (weeks) |
|---|---|---|---|---|---|
| 1 | 1 | Yes | Yes | None | 24 |
| 2 | 1 | Yes | Yes | None | 48 |
| 3 | 1 | No | Yes | None | 24 |
| 4 | 1 | Yes | No | None | 48+ |
| 5 | 1 | Yes | Yes | None | 16 |
| 6 | 1 | No | Yes | Hyperthyroidism (6); Hypothyroidism (12) | 24 |
| 7 | 2 | No | Yes | Hypothyroidism (36) | 36+ |
| 8 | 2 | Yes | Yes | Pancreatitis (30) | 48 |
| 9 | 2 | Yes | Yes | None | 24 |
| 10 | 2 | Yes | Yes | None | 24+ |
| 11 | 2 | No | Yes | Hyperthyroidism (18) | 48 |
| 12 | 2 | No | Yes | Adrenal Insufficiency (38) | 72+ |
| 13 | 3 | Yes | Yes | Elevated TSH (9) | 36+ |
| 14 | 3 | Yes | No | None | 24 |
| 15 | 3 | Yes | Yes | None | 24 |
| 16 | 3 | Yes | No | Hyperthyroidism (3) | 12 |
| 17 | 3 | No | Yes | None | 12 |
aImmune-related adverse events that were at least possibly related to pembrolizumab and /or pTVG vaccine are listed